Clinicopathologic Features and Difference in Prognosis in Synchronous and Metachronous Hepatic Metastases of Gastric Cancer.
10.5230/jkgca.2009.9.3.128
- Author:
Jong Dae KIM
1
;
Taekyung HA
;
Sungjoon KWON
Author Information
1. Department of Surgery, Hanyang University College of Medicine, Seoul, Korea. sjkwon@hanyang.ac.kr
- Publication Type:Original Article
- Keywords:
Gastric cancer;
Liver metastasis;
Synchronous;
Metachronus;
Prognosis
- MeSH:
Cohort Studies;
Humans;
Liver;
Neoplasm Metastasis;
Prognosis;
Retrospective Studies;
Stomach Neoplasms;
Survival Rate
- From:Journal of the Korean Gastric Cancer Association
2009;9(3):128-135
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The aim of this study was to compare synchronous and metachronous hepatic metastases in patients with gastric cancer to determine clinicopathologic features and differences in prognosis as a function of the timing of the metastasis and the treatment modality rendered. MATERIALS AND METHODS: Sixty-seven patients who were diagnosed with gastric cancer metastatic to the liver and treated at the Hanyang University Hospital between June 1992 and December 2006 were retrospectively analyzed to study the pertinent clinicopathologic features and effect of treatment methods. RESULTS: There was a significant difference with respect to lymphatic (P=0.041) and vascular invasion (P=0.036) in comparing the clinicopathologic features between the patients with synchronous and metachronous hepatic metastases. The 1-year survival rate and median survival time of patients with gastric cancer and liver metastases were 38.9% and 9.2 months in the entire patient cohort, 30.9% and 9.2 months in the synchronous group, and 44.5% and 9.7 months in the metachronus group, respectively (P=0.436). The group of patients undergoing local treatment (such as surgery and radiologic intervention) followed by systemic chemotherapy, the group of patients receiving systemic chemotherapy only, and the untreated group of patients were compared, and there was no difference between the synchronous and metachronous groups. The synchronous and metachronous groups had high survival rates with local treatment. CONCLUSION: In patients with gastric cancer and liver metastases, there was no difference in prognosis based on the timing of the hepatic metastases. Independent of the timing of hepatic metastasis, aggressive treatment, such as surgery and radiologic intervention, may help improve the prognosis.
